View in EDS

TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.

Saved in:

Bibliographic Details
Title:	TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
Authors:	Hoshi-Kadonosawa Y; National Cancer Institute Bethesda United States., Reinhold WC; National Cancer Institute Bethesda, MD United States., Taniyama D; National Cancer Institute United States., Inoue Y; United States National Library of Medicine Bethesda United States., Luna A; United States National Library of Medicine Bethesda, MD United States., Kumar S; National Cancer Institute Bethesda, MD United States., Sun NY; National Cancer Institute Bethesda, MD United States., Kim YS; National Cancer Institute Bethesda United States., Yin JJ; National Cancer Institute Bethesda, MD United States., Roper N; National Cancer Institute Bethesda, Maryland United States., Sowalsky AG; National Cancer Institute Bethesda, MD United States., Figg WD; National Cancer Institute Bethesda, MD United States., Takebe N; OU Health Stephenson Cancer Center Oklahoma City, Oklahoma United States., Pommier Y; National Cancer Institute Bethesda, MD United States.
Source:	Molecular cancer therapeutics [Mol Cancer Ther] 2026 Apr 22. Date of Electronic Publication: 2026 Apr 22.
Publication Type:	Journal Article
Journal Info:	Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1538-8514
DOI:	10.1158/1535-7163.MCT-26-0011